Lantheus (NASDAQ:LNTH) Receives Buy Rating from Truist Financial

Lantheus (NASDAQ:LNTH)‘s stock had its “buy” rating reissued by research analysts at Truist Financial in a research note issued to investors on Friday,Benzinga reports. They presently have a $120.00 price objective on the medical equipment provider’s stock, down from their previous price objective of $135.00. Truist Financial’s price objective would suggest a potential upside of 37.14% from the company’s current price.

Several other research analysts have also commented on LNTH. Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday. Finally, B. Riley raised their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $0.81 during midday trading on Friday, hitting $87.50. The company’s stock had a trading volume of 1,619,155 shares, compared to its average volume of 913,265. The business’s fifty day simple moving average is $107.33 and its two-hundred day simple moving average is $95.91. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a market capitalization of $6.08 billion, a price-to-earnings ratio of 14.56 and a beta of 0.51.

Insider Activity at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Large investors have recently bought and sold shares of the business. Moloney Securities Asset Management LLC acquired a new stake in Lantheus during the 3rd quarter worth $1,066,000. Hancock Whitney Corp boosted its stake in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 14,639 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in Lantheus during the 2nd quarter worth $290,000. Pitcairn Co. boosted its stake in Lantheus by 117.0% during the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock worth $521,000 after purchasing an additional 4,509 shares during the period. Finally, Hillsdale Investment Management Inc. acquired a new stake in shares of Lantheus in the 1st quarter worth $4,151,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.